Several studies have reported that the PI3K/AKT/mTOR pathway is excessively activated in more than 50% of cases of AML, up to 88% of cases of ALL, and also in cases of chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL).14, 15. Here, MTOR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.